News

Review of drug subsidy scheme delayed as test case looms

BMJ 2006; 333 doi: 10.1136/bmj.39062.420995.DB (Published 14 December 2006)
Cite this as: BMJ 2006;333:1239.3

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Bob Burton
  1. 1Canberra

    A review of the pharmaceuticals provisions of the Australia-United States free trade agreement has been deferred until after the announcement of the outcome of a landmark appeal.

    The appeal by Eli Lilly Australia against the decision not to include the osteoporosis drug teriparatide (Forteo) in the Australian government's Pharmaceutical Benefits Scheme will be decided upon by an independent reviewer and is expected early next year.

    The decision is seen by the drug industry as a test case on the effectiveness of concessions won when the agreement was concluded in 2004 (BMJ 2004;328:604). On four occasions, the company's …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular